(Press-News.org) A BMJ investigation into the top-selling diabetes drug rosiglitazone (Avandia) raises concerns about its safety and the whole system by which drugs are evaluated, regulated, and promoted around the world.
BMJ Editor in Chief, Dr Fiona Godlee, believes that the drug should not have been licensed and should now be withdrawn. She also calls for more robust regulatory processes and better access to the raw data used to license drugs to allow scrutiny by the scientific community.
The investigation reveals that in July the Commission on Human Medicines advised the MHRA to withdraw the drug as the "risks of rosiglitazone outweigh its benefits and that it no longer has a place on the UK market".
In light of these concerns, doctors are also advising that no new patients should be started on rosiglitazone, and patients already taking it should be reviewed and alternative treatments considered. Those at higher risk of heart disease should be advised to stop taking the drug.
Rosiglitazone, manufactured by Glaxo SmithKline (GSK) was approved by the US Food and Drug Administration (FDA) in 1999 and by the European Medicines Agency (EMA) in 2000 to help lower blood sugar levels in patients with type 2 diabetes.
Since its approval, several studies have suggested that rosiglitazone may lead to a small overall increase in the risk of heart attacks, but in July an FDA scientific advisory panel recommended that it was safe enough to stay on the market.
In her report, Dr Deborah Cohen investigations editor of the BMJ, obtained documents under the Freedom of Information Act that note a paucity of evidence during the European approval process and outline concerns from some panel members about the long term risks and benefits of rosiglitazone. Other experts have since remarked on the poor evidence base and lack of long term data on cardiovascular safety.
The report also raises concerns about the quality of the data used by GSK to show that rosiglitazone did not lead to increased heart problems compared to other diabetes drugs, the lack of publicly available trial results for independent scientific scrutiny, a lack of transparency in the European system, and the ability of the European regulator to assess individual patient data.
Pressures on regulatory agencies by diabetologists to approve rosiglitazone, and failures by the agencies to act swiftly on emerging safety information are also highlighted in the report.
Two experts comment on today's report.
Professor Nick Freemantle at the University of Birmingham, calls for an overhaul in the standards of regulatory trials to minimise the risk of a similar situation occurring in other clinical areas in the future. "In order to learn from our mistakes, we must improve the quality of safety data from clinical trials on all new health care interventions, not just antidiabetic drugs," he says.
Professor John S.Yudkin of University College London believes doctors must focus on what matters to patients. "Ten years after the release of rosiglitazone, we still cannot accurately quantify the harm to which we were exposing our patients," he says. He admits that some of the blame lies with clinicians for not insisting on better proof of long-term benefit, and adds: "We need to be absolutely certain that our long term treatments for type 2 diabetes are not causing the very harm they are meant to prevent. And if the regulatory bodies do not insist on clear evidence of greater benefit than harm, they are failing in their basic purpose."
INFORMATION:
Links to the editorial and commentary are below. The feature is available by emailing Deborah Cohen.
END
There may be better ways to engineer the planet's climate to prevent dangerous global warming than mimicking volcanoes, a University of Calgary climate scientist says in two new studies.
"Releasing engineered nano-sized disks, or sulphuric acid in a condensable vapour above the Earth, are two novel approaches. These approaches offer advantages over simply putting sulphur dioxide gas into the atmosphere," says David Keith, a director in the Institute for Sustainable Energy, Environment and Economy and a Schulich School of Engineering professor.
Keith, a global leader ...
PASADENA, Calif.—Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. The process—developed by Niles Pierce, associate professor of applied and computational mathematics and bioengineering at Caltech, and his colleagues—uses small RNA molecules that can be programmed to attack only specific cancer cells; then, by changing shape, those molecules cause the cancer cells to self-destruct.
In conventional chemotherapy treatments for cancer, patients are given drugs that target cell behaviors typical ...
Palo Alto, CA—Using sophisticated airborne imaging and structural analysis, scientists at the Carnegie Institution's Department of Global Ecology mapped more than 40,000 termite mounds over 192 square miles in the African savanna. They found that their size and distribution is linked to vegetation and landscape patterns associated with annual rainfall. The results reveal how the savanna terrain has evolved and show how termite mounds can be used to predict ecological shifts from climate change. The research is published in the September 7, 2010, advanced online edition ...
Only 45 percent of the 354 million annual visits for acute care in the United States are made to patients' personal physicians, as Americans increasingly make busy emergency departments, specialists or outpatient care departments their first point of contact for treatment of new health problems or a flare up of a chronic condition like asthma or diabetes.
The findings, which appear in the September edition of Health Affairs, do not bode well for the nation's already busy and frequently undermanned emergency rooms. While fewer than five percent of doctors across the ...
UPTON, NY — A brain-scanning study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, conducted with collaborators from Stony Brook University, reveals that an oral dose of methylphenidate, commonly known as Ritalin, improves impaired brain function and enhances cognitive performance in people who are addicted to cocaine. The study — to be published in the Proceedings of the National Academy of Sciences the week of September 6, 2010 — suggests that methylphenidate, combined with cognitive interventions, may have a role in facilitating recovery from ...
A team made up of members of the University of Oviedo (UO) and the Complutense University of Madrid (UCM) have gathered together all findings of the woolly mammoth, the woolly rhinoceros and the reindeer in the Iberian Peninsula to show that, although in small numbers, these big mammals, prehistoric indicators of cold climates, already lived in this territory some 150,000 years ago.
The presence of the woolly mammoth (Mammuthus primigenius), the woolly rhinoceros (Coelodonta antiquitatis), the reindeer (Rangifer tarandus), and to a lesser extent the wolverine (Gulo gulo), ...
Researchers have developed a new data transmission system that could substantially improve the transmission capacity and energy efficiency of the world's optical communication networks.
Transmission of data through optical networks is currently limited by 'phase noise' from optical amplifiers and 'cross talk' induced by interaction of the signal with the many other signals (each at a different wavelength) simultaneously circulating through the network. 'Phase noise' is the rapid, short-term, random fluctuations in the phase of a signal, which affects the quality of the ...
A new study from Sweden's Karolinska Institutet suggests that bipolar disorder – or manic-depressive disorder – does not increase the risk of committing violent crime. Instead, the over-representation of individuals with bipolar disorder in violent crime statistics is almost entirely attributable to concurrent substance abuse.
The public debate on violent crime usually assumes that violence in the mentally ill is a direct result of the perpetrator's illness. Previous research has also suggested that patients with bipolar disorder – also known as manic-depressive disorder ...
PHILADELPHIA, PA. (September 7, 2010)—Aurora-A kinase (AurA) is an enzyme that is hyperactive in many cancers and drives tumor cell proliferation. Several AurA inhibitors are currently being tested in clinical trials to see if they slow tumor growth. Now, researchers in the Developmental Therapeutics Program at Fox Chase Cancer Center have identified an activation signal for AurA. They report in the September 7 issue of Nature Communications that a quick increase in the calcium concentration in a cell rapidly triggers AurA kinase activity. The discovery may lead to drug ...
The methodology, which has been used in this research in collaboration with the Universidad Europea de Madrid, is based on the Open-Path FTIR technique which takes advantage of specific properties of gases in order to detect them: they absorb radiation only in certain wave lengths which are always the same and particular to each gas. Many gases have absorption lines or bands in the infrared, for which this area of the electromagnetic spectrum is very useful for the remote detection of gases, according to the authors of this research from the UC3M Department of Physics. ...
